Saturday, July 11, 2026

pharma · Advanced Gastric or Gastroesophageal Junction Cancer · Dwarfism

GeneScience Pharmaceuticals Co

GeneScience Pharmaceuticals Co clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
30 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Employees
30
Programs
3
Drugs
4
Patents
0
Intelligence · Clinical Programs

GeneScience Pharmaceuticals Co projects

3 ClinicalTrials.gov programs sponsored by GeneScience Pharmaceuticals Co.

GeneScience Pharmaceuticals Co has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Gentuximab

    Changchun GeneScience Pharmaceutical Co.,

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial
  2. PEG-somatropin

    Changchun GeneScience Pharmaceutical Co.,

    Dwarfism

    phase 2 small molecule active

    1 trial
  3. PEG-somatropin

    Changchun GeneScience Pharmaceutical Co.,

    Growth Hormone Deficiency

    approved mab active

    1 trial

Frequently asked questions

How many clinical projects does GeneScience Pharmaceuticals Co have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.